

# Introduction

• The deacetylase LpxC enzyme is present in *E. coli* and has been demonstrated to be essential for it's growth. It catalyses the first committed step of lipid A biosynthesis in the cell wall, which serves as a permeability barrier that protects the bacterium from many antibiotics, such as erythromycin.<sup>1</sup>

LpxC has been identified in a gram-negative pathogen *Pseudomonas* aeruginosa which has been documented as a therapeutic problem because of nosocomial infection and antimicrobial resistance.

• The LpxC protein of *P. aeruginosa* is encoded by a homologous gene and catalyzes the same reaction as in *E. coli*. These data on sequence similarity and functional identity suggest that it should be possible to discover LpxC inhibitors active against both E. coli and P. aeruginosa. However, none of the early E. coli LpxC inhibitors, were able to inhibit the growth of *P. aeruginosa*.<sup>3</sup>

• Aim of this work was to study the potentially important structural differences in active sites of both proteins responsible for making the inhibitors selective for *E. coli* as compared to *P. aeruginosa* LpxC.

### Methodology

• Homology modeling: Homology models for the LpxCs of both organisms were developed and validated on the basis of a 3D profile and PROCHECK.

Molecular electrostatic potential (MEP) based surface and cavity-depth analysis

**Docking:** A cross-docking analysis of reported inhibitors for both proteins was performed to reveal selective binding modes.

## Homology modeling

• Template Selection

Name	Source	Local Identity (%)	PDB ID	Resolution (Å)
P.a. LpxC	Aquifex aeolicus Deacetylase LpxC	37.1%	1P42	2.00
	AalpxcTU-514 Complex	37.1%	1XXE	NA
<i>E. coli</i> LpxC	TNSA, a catalytic component of the TN7 transposition system	23.1%	1F1Z	2.40
	Aquifex aeolicus Deacetylase LpxC	32.9%	1P42	2.00
	AalpxcTU-514 Complex	32.9%	1XXE	NA

Permutation selection of different loop candidates and side-chain rotamers

Minimization of the models


Addition of Zn<sup>2+</sup> and water molecules


# E. coli vs. P. aeruginosa deacetylase LpxC inhibitors selectivity: Surface and Cavity depth based analysis

### **Rameshwar U. Kadam, Amol V. Shivange and Nilanjan Roy**

Centre of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, Sector 67, S.A.S Nagar, Punjab 160 062, INDIA


**Topology of** *E. coli* and *P. aeruginosa* LpxC






Structural topology of *E. coli* LpxC (a) and *P. aeruginosa* LpxC (b). α helices are colored red,  $\beta$  strands are colored green, cyan, yellow, and blue. N and C indicate the N-terminal and C-terminal regions of the protein.

# E. coli LpxC-P. aeruginosa LpxC Active-Site Analysis




Active site residues of E. coli LpxC (magenta) superpositioned onto P. aeruginosa LpxC (green). The differences are highlighted by labelled residues in the picture.

# **MEP Surface Analysis**



*E. coli* LpxC




P. aeruginosa LpxC

# **Cavity Depth Analysis**

Differences were observed in the cavity depths at the active site cleft near the Zn<sup>+2</sup> binding pocket. E. coli LpxC presented a depth value of 4.4 to 5.2 Å whereas it was 4.7 to 6.3 Å for *P. aeruginosa* LpxC.

# **Docking Analysis**



Selectively docked molecules in active sites of the homology models. Figures a & b indicate docking of *E. coli* inhibitor and c& d indicate docking of the *P*. aeruginosa inhibitor into the E. coli and P. aeruginosa LpxC resp.

### Conclusions

- with broad-spectrum LpxC inhibitory activity

## Publication

Kadam *et al*, J. Chem. Inf. Model., 2007, 47, 1215-1224

### References

- 1) Young et al., J. Biol. Chem. 1995, 270, 30384-30391
- 2) Mdluli et at., Antimicrob. Agents Chemother, 2006, 50, 2178-2184

• Reliable homology models of *E. coli* and *P. aeruginosa* LpxCs were created.

• Several minor but potentially important structural differences in the catalytic domains of the two proteins were identified. These differences could be responsible for variable activities of the inhibitors in the two proteins.

• The differences identified in this study might facilitate the design of inhibitors